JP7781792B2 - セレブロン結合化合物、その組成物及びそれによる治療方法 - Google Patents

セレブロン結合化合物、その組成物及びそれによる治療方法

Info

Publication number
JP7781792B2
JP7781792B2 JP2022580090A JP2022580090A JP7781792B2 JP 7781792 B2 JP7781792 B2 JP 7781792B2 JP 2022580090 A JP2022580090 A JP 2022580090A JP 2022580090 A JP2022580090 A JP 2022580090A JP 7781792 B2 JP7781792 B2 JP 7781792B2
Authority
JP
Japan
Prior art keywords
mmol
trans
cyclohexyl
trifluoromethyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022580090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533203A5 (https=
JP2023533203A (ja
Inventor
ディ アレキサンダー，マシュー
ディ コレア，マシュー
ダルビー，ディーパク
ヘザー シャロン グラント，バージニア
ハンセン，ジョシュア
サード，ロイ エル ハリス，ザ
ジェイ ホーン，エバン
ホアン，デフア
メイン，クリストファー
ノリス，スティーブン
プラントヴァン－クレニツキー，ヴェロニク
ジェイ サピエンザ，ジョン
テラニ，リダ
ダブリュー ホワイトフィールド，ブランドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2023533203A publication Critical patent/JP2023533203A/ja
Publication of JP2023533203A5 publication Critical patent/JP2023533203A5/ja
Priority to JP2025203650A priority Critical patent/JP2026035702A/ja
Application granted granted Critical
Publication of JP7781792B2 publication Critical patent/JP7781792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2022580090A 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法 Active JP7781792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203650A JP2026035702A (ja) 2020-06-24 2025-11-26 セレブロン結合化合物、その組成物及びそれによる治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043555P 2020-06-24 2020-06-24
US63/043,555 2020-06-24
PCT/US2021/038618 WO2021262810A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203650A Division JP2026035702A (ja) 2020-06-24 2025-11-26 セレブロン結合化合物、その組成物及びそれによる治療方法

Publications (3)

Publication Number Publication Date
JP2023533203A JP2023533203A (ja) 2023-08-02
JP2023533203A5 JP2023533203A5 (https=) 2024-06-07
JP7781792B2 true JP7781792B2 (ja) 2025-12-08

Family

ID=79032408

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580090A Active JP7781792B2 (ja) 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法
JP2025203650A Pending JP2026035702A (ja) 2020-06-24 2025-11-26 セレブロン結合化合物、その組成物及びそれによる治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203650A Pending JP2026035702A (ja) 2020-06-24 2025-11-26 セレブロン結合化合物、その組成物及びそれによる治療方法

Country Status (17)

Country Link
US (3) US11634407B2 (https=)
EP (1) EP4171566A4 (https=)
JP (2) JP7781792B2 (https=)
KR (1) KR20230027066A (https=)
CN (2) CN120441548A (https=)
AR (1) AR122723A1 (https=)
AU (1) AU2021296833A1 (https=)
BR (1) BR112022025933A2 (https=)
CA (1) CA3182325A1 (https=)
CL (1) CL2022003719A1 (https=)
CO (1) CO2022018653A2 (https=)
IL (1) IL299256A (https=)
MX (1) MX2022015757A (https=)
PE (1) PE20231746A1 (https=)
SA (1) SA522441857B1 (https=)
TW (1) TW202216680A (https=)
WO (1) WO2021262810A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
CN117561249A (zh) * 2021-06-25 2024-02-13 细胞基因公司 Cereblon结合化合物、其组合物及其用于治疗的方法
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483A (zh) 2006-03-09 2007-09-12 陈德桂 调节雄激素受体活性的乙内酰脲衍生物的组成及其应用
US20160214972A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
US20190076542A1 (en) 2016-05-10 2019-03-14 C4 Theraprutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2020051260A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20200199073A1 (en) 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483A (zh) 2006-03-09 2007-09-12 陈德桂 调节雄激素受体活性的乙内酰脲衍生物的组成及其应用
US20160214972A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20190076542A1 (en) 2016-05-10 2019-03-14 C4 Theraprutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
WO2020051260A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20200199073A1 (en) 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
AR122723A1 (es) 2022-09-28
US20250188056A1 (en) 2025-06-12
CA3182325A1 (en) 2021-12-30
EP4171566A4 (en) 2024-07-24
SA522441857B1 (ar) 2024-07-21
PE20231746A1 (es) 2023-11-06
US20210403454A1 (en) 2021-12-30
US20230242509A1 (en) 2023-08-03
IL299256A (en) 2023-02-01
US11634407B2 (en) 2023-04-25
JP2026035702A (ja) 2026-03-04
WO2021262810A1 (en) 2021-12-30
CN115835866B (zh) 2025-05-02
KR20230027066A (ko) 2023-02-27
AU2021296833A1 (en) 2023-01-19
CL2022003719A1 (es) 2023-05-12
CN120441548A (zh) 2025-08-08
JP2023533203A (ja) 2023-08-02
MX2022015757A (es) 2023-01-19
US12103920B2 (en) 2024-10-01
EP4171566A1 (en) 2023-05-03
CN115835866A (zh) 2023-03-21
TW202216680A (zh) 2022-05-01
CO2022018653A2 (es) 2023-03-27
BR112022025933A2 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
JP7781792B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP7778095B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP7781083B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
KR102864064B1 (ko) 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
JP2024526191A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526182A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
EA047871B1 (ru) Соединения, связывающие цереблон, композиции на их основе и способы лечения с их применением
US20250100995A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251126

R150 Certificate of patent or registration of utility model

Ref document number: 7781792

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150